Automated and streamlined manufacturing of TIL therapies [WEBINAR]

For more information visit: www.miltenyibiotec.com/applications/by-cell-type/t… This webinar explores groundbreaking advancements in TIL (tumor-infiltrating lymphocyte) therapy for cancer treatment, following recent FDA approval. Learn about a novel, automated TIL manufacturing process that simplifies production and reduces errors, presented by Dr. Ian Hardy of Miltenyi Biotec. Professor Lars Ny from the University of Gothenburg will also share early insights into using TILs for targeted treatment in patients with liver metastases from ocular melanoma.

Miltenyi Biotec is a global leader innovating technologies and services for patient-specific cell and gene therapies, turning scientific discoveries into practical treatments for personalized medicine. Having pioneered a groundbreaking method of cell separation, Miltenyi Biotec continues to sets industry standards today. With over 35 years of expertise, it supports customers in biomedical discoveries, translating them into clinical applications to enable access to new therapies for patients. Miltenyi Biotec focuses on providing integrated, advanced solutions to address complex challenges in the treatment of cancers, autoimmune diseases, and inherited disorders. Through its Miltenyi Bioindustry division, it provides expert guidance to therapy developers, helping them efficiently and cost-effectively navigate the path from process development to commercialization. Miltenyi Biotec is headquartered in Bergisch Gladbach and has a global team of 4,900 employees across 24 countries.